1 lineage of Omicron but is already being superseded by sister strain KP.3. Still, Pfizer/BioNTech and Moderna say they expect their new vaccines will retain protective efficacy as the two strains ...

According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month, however, that it has ...

the technology used in the Moderna and Pfizer shots, the researchers said. In clinical trials, J&J's vaccine had shown an 85% efficacy. In subsequent studies in the general population, this figure ...

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.

Roivant Sciences Ltd (ROIV) showcases strong financials and strategic advancements while navigating ongoing litigation and competitive pressures.

Bonus Jun 12, 2000 Jun 28, 2000 May 25, 2000 Bonus Ratio: 1 share(s) for every 1 shares held Bonus--Jul 25, 1977 Bonus Ratio: 4 share(s) for every 5 shares held Bonus--Jul 25, 1972 Bonus Ratio: 2 ...

They might not seem like natural allies, but RFK Jr and the boss of Pfizer had a secret dinner where they discussed how to fix America's health crisis, it has been revealed. Pfizer CEO Albert ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...